EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: RemeGen Co., Ltd.
This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.
This description comes directly from the study's public registry record.
Yongfeng Yang · 010-65384976 · yongfeng.yang@remegen.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Cancer Hospital Affiliated to Chongqing University | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing Medical University First Affiliated Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Union Hospital Affiliated to Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| The First Affiliated Hospital of Lanzhou University | Lanzhou, Gansu, China | Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Recruiting |
| Cancer Hospital Affiliated to Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
+ 66 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07416474